The COVID-19 pandemic has raised many questions about the regulation of drugs in the United States.
One such concern relates to the use of drugs for treatment of COVID-19 that have not yet been FDA approved.
In this video explainer produced by the James E. Rogers College of Law of The University of Arizona, Christopher Robertson, Professor of Law and Associate Dean for Research & Innovation, discusses these issues, including the Right to Try Act and off-label use of pharmaceuticals, with NYU Grossman School of Medicine’s Alison Bateman-House, MPH, PhD.
